Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL5222881

B.CCCC.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.41
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CES1 P23141 8/20 0.33
FAAH O00519 8/20 0.33
CES2 O00748 3/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA7 P43166 1/20 0.33
CA13 Q8N1Q1 1/20 0.33
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL3361058 0.97 EPHX1 (0.43) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL2958868 0.94 EPHX1 (0.41) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL5551211 0.92 EPHX1 (0.40) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL2285727 0.88 ALDH1A1 (0.41) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL1394197 0.87 EPHX1 (0.38) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL3129636 0.86 EPHX1 (0.56) EPHX1CES1FAAHCES2MEN1
Trifluoromethanesulfonic Acid SCHEMBL1851236 0.85 ALDH1A1 (0.39) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL27910342 0.85 ALDH1A1 (0.39) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL27669034 0.85 ALDH1A1 (0.39) EPHX1ALDH1A1L3MBTL1CES1FAAH
Trifluoromethanesulfonic Acid SCHEMBL10865456 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435071-B2 Bryostatin compounds and methods of preparing the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-10-07 US disclosed
US-20240116908-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2024-04-11 US disclosed
US-11746105-B2 Bryostatin compounds and methods of preparing the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-09-05 US disclosed
US-20210292309-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2021-09-23 US disclosed
US-10947221-B2 Bryostatin compounds and methods of preparing the same THE BOARD OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-03-16 US disclosed
US-20190292172-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2019-09-26 US disclosed
EP-3523296-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME The Board of Trustees of the Leland Stanford Junior University (US) 2019-08-14 EP disclosed
WO-2018067382-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2018-04-12 WO disclosed
CN-101675031-B Process for stereoselective preparation of 4-BMA using a chiral auxiliary DAE WOONG PHARMA 2013-12-11 CN disclosed
CN-101675031-A Use the chiral auxiliary(reagent) stereoselectivity to prepare the method for 4-BMA DAE WOONG PHARMA 2010-03-17 CN disclosed
EP-1334092-B1 PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES UNIV MONASH (AU) 2007-05-09 EP disclosed
US-7012142-B2 Process for preparation of bicyclic and polycyclic molecules MONASH UNIVERSITY (AU) 2006-03-14 US disclosed
EP-1334092-A4 PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES UNIV MONASH (AU) 2004-08-11 EP disclosed
US-20040010140-A1 Process for preparation of bicyclic and polycyclic molecules MONASH UNIVERSITY (AU) 2004-01-15 US disclosed
EP-1334092-A1 PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES Monash University (AU) 2003-08-13 EP disclosed
WO-2002034736-A1 PROCESS FOR PREPARATION OF BICYCLIC AND POLYCYCLIC MOLECULES MONASH UNIVERSITY (AU) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746105-B2 Bryostatin compounds and methods of preparing the same PROKR1, PBK, PROKR2 EPHX1 3372/4885ALDH1A1 4077/4885L3MBTL1 2440/4885
US-10947221-B2 Bryostatin compounds and methods of preparing the same PROKR1, PBK, PROKR2 EPHX1 3372/4885ALDH1A1 4077/4885L3MBTL1 2440/4885
US-20040010140-A1 Process for preparation of bicyclic and polycyclic molecules CYP2B6, CYP3A4, NR1H4 EPHX1 1355/4885ALDH1A1 3426/4885L3MBTL1 4572/4885
US-20210292309-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME PROKR1, PBK, PROKR2 EPHX1 3372/4885ALDH1A1 4077/4885L3MBTL1 2440/4885
US-20190292172-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME PROKR1, PBK, PROKR2 EPHX1 3372/4885ALDH1A1 4077/4885L3MBTL1 2440/4885
US-20240116908-A1 BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME PROKR1, PBK, PROKR2 EPHX1 3372/4885ALDH1A1 4077/4885L3MBTL1 2440/4885
US-12435071-B2 Bryostatin compounds and methods of preparing the same PROKR1, PBK, PROKR2 EPHX1 3372/4885ALDH1A1 4077/4885L3MBTL1 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.